| Dr Jeffrey Robert Pappert, MD | |
|
377 Jersey Ave, Ste 590, Jersey City, NJ 07302-4393 | |
| (201) 763-6313 | |
| (201) 763-6062 |
| Full Name | Dr Jeffrey Robert Pappert |
|---|---|
| Gender | Male |
| Speciality | Internal Medicine |
| Experience | 21 Years |
| Location | 377 Jersey Ave, Jersey City, New Jersey |
| Accepts Medicare Assignments | Yes. He accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1164695722 | NPI | - | NPPES |
| 139552ADC | Other | NJ | MEDICARE ID |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 207R00000X | Internal Medicine | 25MA08374200 (New Jersey) | Primary |
| Facility Name | Location | Facility Type |
|---|---|---|
| Jersey City Medical Center | Jersey city, NJ | Hospital |
| Entity Name | Medemerge Llc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1366656431 PECOS PAC ID: 1456340595 Enrollment ID: O20040512000455 |
News Archive
It may be possible to predict the severity of hearing loss for children diagnosed with enlarged vestibular aqueduct, according to a new study published in JAMA-Otolaryngology-Head & Neck Surgery.
Physicians have long been puzzled by a condition called intracranial arterial dolichoectasia, in which the larger arteries of the brain become elongated and misshapen.
A new discovery by Boston University School of Medicine (BUSM) researchers may change how kidney disease is treated in the future.
Amgen and Millennium: The Takeda Oncology Company, a subsidiary of Takeda Pharmaceutical Company Limited , today announced that enrollment in the Phase 3 MONET1 trial evaluating motesanib (AMG 706) in combination with paclitaxel and carboplatin for the first-line treatment of advanced non-small cell lung cancer (NSCLC) has been temporarily suspended following a planned safety data review of 600 patients by the study's independent Data Monitoring Committee (DMC). Motesanib is part of a broad co-development program between Amgen and Takeda.
› Verified 9 days ago
| Entity Name | Practice Associates Medical Group |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1427016385 PECOS PAC ID: 5890703177 Enrollment ID: O20060330000690 |
News Archive
It may be possible to predict the severity of hearing loss for children diagnosed with enlarged vestibular aqueduct, according to a new study published in JAMA-Otolaryngology-Head & Neck Surgery.
Physicians have long been puzzled by a condition called intracranial arterial dolichoectasia, in which the larger arteries of the brain become elongated and misshapen.
A new discovery by Boston University School of Medicine (BUSM) researchers may change how kidney disease is treated in the future.
Amgen and Millennium: The Takeda Oncology Company, a subsidiary of Takeda Pharmaceutical Company Limited , today announced that enrollment in the Phase 3 MONET1 trial evaluating motesanib (AMG 706) in combination with paclitaxel and carboplatin for the first-line treatment of advanced non-small cell lung cancer (NSCLC) has been temporarily suspended following a planned safety data review of 600 patients by the study's independent Data Monitoring Committee (DMC). Motesanib is part of a broad co-development program between Amgen and Takeda.
› Verified 9 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Dr Jeffrey Robert Pappert, MD 20 2nd St, Apt# 906, Jersey City, NJ 07302-3075 Ph: (201) 239-7182 | Dr Jeffrey Robert Pappert, MD 377 Jersey Ave, Ste 590, Jersey City, NJ 07302-4393 Ph: (201) 763-6313 |
News Archive
It may be possible to predict the severity of hearing loss for children diagnosed with enlarged vestibular aqueduct, according to a new study published in JAMA-Otolaryngology-Head & Neck Surgery.
Physicians have long been puzzled by a condition called intracranial arterial dolichoectasia, in which the larger arteries of the brain become elongated and misshapen.
A new discovery by Boston University School of Medicine (BUSM) researchers may change how kidney disease is treated in the future.
Amgen and Millennium: The Takeda Oncology Company, a subsidiary of Takeda Pharmaceutical Company Limited , today announced that enrollment in the Phase 3 MONET1 trial evaluating motesanib (AMG 706) in combination with paclitaxel and carboplatin for the first-line treatment of advanced non-small cell lung cancer (NSCLC) has been temporarily suspended following a planned safety data review of 600 patients by the study's independent Data Monitoring Committee (DMC). Motesanib is part of a broad co-development program between Amgen and Takeda.
› Verified 9 days ago
Dr. Alita Logrono Dizon, M.D. Internal Medicine Medicare: Accepting Medicare Assignments Practice Location: 377 Jersey Ave, Suite 460, Jersey City, NJ 07302 Phone: 201-332-4110 Fax: 201-332-4122 | |
Mrs. Sonia Castaneda Velasco, MD Internal Medicine Medicare: Not Enrolled in Medicare Practice Location: 172 Newark Ave, Jersey City, NJ 07302 Phone: 201-332-4727 Fax: 201-332-4157 | |
Dr. Vladimir Znamensky, M.D. Internal Medicine Medicare: Accepting Medicare Assignments Practice Location: 120 Franklin St, Jersey City, NJ 07307 Phone: 201-216-9791 Fax: 201-216-1362 | |
Saira Shah, MD Internal Medicine Medicare: Accepting Medicare Assignments Practice Location: 355 Grand St, Medicine Dept,3rd Floor, Jersey City, NJ 07302 Phone: 201-915-2000 | |
Zorayda Olaya De Leon, MD Internal Medicine Medicare: Accepting Medicare Assignments Practice Location: 311 Palisade Ave, Jersey City, NJ 07307 Phone: 201-963-5500 Fax: 201-963-5563 | |
Dr. Jared Saul Krok, M.D. Internal Medicine Medicare: Accepting Medicare Assignments Practice Location: 355 Grand St, Jersey City, NJ 07302 Phone: 201-915-2431 | |
Merwin F Richard, M.D Internal Medicine Medicare: Accepting Medicare Assignments Practice Location: 550 Newark Ave, Ste 307, Jersey City, NJ 07306 Phone: 201-418-9111 Fax: 201-418-9118 |